Lehigh Valley Heart Institute, Lehigh Valley Health Network, Allentown, PA.
Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY.
Curr Probl Cardiol. 2022 Sep;47(9):100859. doi: 10.1016/j.cpcardiol.2021.100859. Epub 2021 Apr 3.
Global incidence and prevalence of hypertension continues to increase and remains a significant challenge. The ever-increasing number of cases are due to comorbid conditions such as obesity and diabetes, as well as lifestyle indiscretions such as excessive salt intake. Hypertension, congestive heart failure, and kidney disease are all conditions resulting from abnormal Renin-Angiotensin-Aldosterone activation and adverse remodeling. Firibastat, a novel Brain Aminopeptidase inhibitor, may be able to help achieve blood pressure control in those with resistant hypertension. In this review article, we will discuss the biochemical pathway of firibastat and various trials assessing drug efficacy in animals and humans. This drug has the potential to curb the risk of uncontrolled hypertension and help improve long term cardiovascular morbidity and mortality.
全球高血压的发病率和患病率持续上升,仍然是一个重大挑战。病例不断增加的原因是肥胖症和糖尿病等合并症以及摄入过多盐分等不良生活习惯。高血压、充血性心力衰竭和肾脏疾病都是由于肾素-血管紧张素-醛固酮系统异常激活和不良重构引起的。新型脑氨肽酶抑制剂 Firibastat 可能有助于控制难治性高血压患者的血压。在这篇综述文章中,我们将讨论 Firibastat 的生化途径以及评估该药在动物和人体中疗效的各种试验。该药物有可能降低高血压失控的风险,有助于改善长期心血管发病率和死亡率。